ELI LILLY AND COMPANY Other Additional Capital
ELI LILLY AND COMPANY (LLY) had Other Additional Capital of $55.00 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:OtherAdditionalCapital · last filed 2026-08-05
- 2026-06-30: Other Additional Capital $55.00M.
- 2026-03-31: Other Additional Capital $19.00M.
- 2025-12-31: Other Additional Capital $22.00M.
- 2024-12-31: Other Additional Capital $31.00M.
| Period end | Other Additional Capital |
|---|---|
| 2026-06-30 | $55.00M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $19.00M 10-Q · filed 2026-04-30 |
| 2025-12-31 | $22.00M 10-Q · filed 2026-08-05 |
| 2024-12-31 | $31.00M 10-K · filed 2026-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |